End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.09 CAD | 0.00% | 0.00% | -10.00% |
04-01 | Willow Biosciences Narrows 2023 Loss YOY | MT |
03-29 | Willow Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2022 | 821K 601K | Sales 2023 | 1.17M 858K | Capitalization | 12.42M 9.09M |
---|---|---|---|---|---|
Net income 2022 | -14M -10.25M | Net income 2023 | -13M -9.51M | EV / Sales 2022 | -0.95 x |
Net cash position 2022 | 15.01M 10.98M | Net cash position 2023 | 1.63M 1.19M | EV / Sales 2023 | 9.21 x |
P/E ratio 2022 |
-0.96
x | P/E ratio 2023 |
-0.95
x | Employees | 19 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 72.66% |
Current month | -10.00% | ||
1 month | -10.00% | ||
3 months | -5.26% | ||
6 months | +12.50% | ||
Current year | -10.00% |
Managers | Title | Age | Since |
---|---|---|---|
Chris Savile
CEO | Chief Executive Officer | - | 19-04-11 |
Travis Doupe
DFI | Director of Finance/CFO | - | 19-04-11 |
Trish Choudhary
CTO | Chief Tech/Sci/R&D Officer | - | 19-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jim Lalonde
CHM | Chairman | 63 | 23-02-20 |
Donald Archibald
BRD | Director/Board Member | 63 | 19-04-11 |
Director/Board Member | 51 | 19-04-11 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 0.09 | 0.00% | 33,000 |
24-04-24 | 0.09 | 0.00% | 1,000 |
24-04-23 | 0.09 | 0.00% | 18,151 |
End-of-day quote Toronto S.E., April 25, 2024
More quotes1st Jan change | Capi. | |
---|---|---|
-10.00% | 8.36M | |
-4.06% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+55.70% | 25.23B | |
-16.09% | 15.36B | |
-9.14% | 11.95B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
+5.09% | 8.71B |
- Stock Market
- Equities
- WLLW Stock